Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of L-Norepinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 3/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | BLM | P54132 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | APEX1 | P27695 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Norepinephrine SCHEMBL3489077 | 1.00 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL29371849 | 1.00 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL2610 | 1.00 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| Norepinephrine SCHEMBL29399946 | 1.00 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| Norepinephrine SCHEMBL2609 | 1.00 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| Norepinephrine SCHEMBL2429869 | 1.00 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL4155242 | 0.98 | BLM (0.96) | TDP1KDM4EBLMMAPTADRB2 | |
| Norepinephrine SCHEMBL10576062 | 0.98 | TDP1 (0.96) | TDP1KDM4EBLMMAPTADRB2 | |
| Norepinephrine SCHEMBL3334108 | 0.98 | TDP1 (0.96) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL17504429 | 0.98 | TDP1 (0.96) | TDP1KDM4EBLMMAPTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117820138-A | Circulating chiral resolution method of norepinephrine | 蚌埠丰原医药科技发展有限公司 | 2024-04-05 | — | — | CN | claimed |
| EP-4244610-A1 | PROGRAMMABLE NANO-REACTORS FOR STOCHASTIC SENSING (PNRSS) | Nanjing University (CN) | 2023-09-20 | — | — | EP | claimed |
| CN-116635712-A | Programmable nanoreactor for random sensing (PNRSS) | 南京大学 | 2023-08-22 | — | — | CN | claimed |
| US-RE49555-E1 | Process for producing a stable low concentration, injectable solution of noradrenaline | SINTETICA S.A. (CH) | 2023-06-20 | — | — | US | claimed |
| US-RE49443-E1 | Process for producing a stable low concentration, injectable solution of noradrenaline | SINTETICA S.A. (CH) | 2023-03-07 | — | — | US | claimed |
| US-RE49422-E1 | Process for producing a stable low concentration, injectable solution of noradrenaline | SINTETICA S.A. (CH) | 2023-02-21 | — | — | US | claimed |
| WO-2022100147-A1 | PROGRAMMABLE NANO-REACTORS FOR STOCHASTIC SENSING (PNRSS) | NANJING UNIVERSITY (CN) | 2022-05-19 | — | — | WO | claimed |
| US-20250272550-A1 | MEMRISTIVE SELF-LEARNING SPIKING FEEDBACK LOOPS-BASED NEURAL NETWORKS WITH SPIKE-TIMING-DEPENDENT PLASTICITY (STDP) | B-RAIN ARK FZ-LLC (AE) | 2025-08-28 | — | — | US | disclosed |
| CN-116162034-B | Racemic noradrenal gland chiral resolution method of element | 蚌埠丰原医药科技发展有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119757509-A | Application of cyclodextrin in analysis of catecholamine molecular isomers and analysis method | 常州华班亚生物科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-117820138-A | Circulating chiral resolution method of norepinephrine | 蚌埠丰原医药科技发展有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20230400474-A1 | PROGRAMMABLE NANO-REACTORS FOR STOCHASTIC SENSING (PNRSS) | NANJING UNIVERSITY (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230398070-A1 | STABLE, INJECTABLE NORADRENALINE SOLUTIONS FREE OF ANTIOXIDANTS | SINTETICA S A (CH) | 2023-12-14 | — | — | US | disclosed |
| US-RE49555-E1 | Process for producing a stable low concentration, injectable solution of noradrenaline | SINTETICA S.A. (CH) | 2023-06-20 | — | — | US | disclosed |
| CN-116162034-A | Chiral resolution method of racemic norepinephrine | 蚌埠丰原医药科技发展有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-RE49443-E1 | Process for producing a stable low concentration, injectable solution of noradrenaline | SINTETICA S.A. (CH) | 2023-03-07 | — | — | US | disclosed |
| US-RE49422-E1 | Process for producing a stable low concentration, injectable solution of noradrenaline | SINTETICA S.A. (CH) | 2023-02-21 | — | — | US | disclosed |
| US-20220233473-A1 | INJECTABLE SOLUTION OF NOREPINEPHRINE | CUMBERLAND PHARMACEUTICALS INC. (US) | 2022-07-28 | — | — | US | disclosed |
| WO-2022100147-A1 | PROGRAMMABLE NANO-REACTORS FOR STOCHASTIC SENSING (PNRSS) | NANJING UNIVERSITY (CN) | 2022-05-19 | — | — | WO | disclosed |
| CN-110133163-B | Method for detecting noradrenaline component ratio of medicines containing multiple types of tartaric acid | 远大医药（中国）有限公司 | 2022-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220233473-A1 | INJECTABLE SOLUTION OF NOREPINEPHRINE | SLC6A2, SLC6A3, SLC18A1 | ADRB2 31/4885ADRB1 18/4885ADRA2A 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.